alemtuzumab GZ402673

DRUG4 trials

Conditions

Multiple SclerosisProgressive Multiple SclerosisRelapsing Remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 1

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

CompletedNCT02583594

Genzyme, a Sanofi CompanyProgressive Multiple Sclerosis

Start: 2015-12-06End: 2021-03-01Updated: 2021-03-10

Phase 3

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

TerminatedNCT03368664

Genzyme, a Sanofi CompanyMultiple Sclerosis

Start: 2017-10-24End: 2025-09-08Updated: 2025-11-26

Phase 4

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

CompletedNCT02205489

Genzyme, a Sanofi CompanyRelapsing-remitting Multiple Sclerosis

Start: 2014-10-31End: 2016-04-30Updated: 2016-06-09

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

CompletedNCT02255656

Genzyme, a Sanofi CompanyRelapsing Remitting Multiple Sclerosis

Start: 2015-01-07End: 2020-07-15Updated: 2022-03-28

Therapeutic Advances in Neurological Disorders2025-01-012 citations

SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.

2024-11-06

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Therapeutic Advances in Neurological Disorders2023-01-0118 citations

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS

Multiple Sclerosis Journal2021-08-1131 citations

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.

2021-06-243 citations

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Therapeutic Advances in Neurological Disorders2021-01-0144 citations

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.

2020-12-2414 citations

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

CNS Drugs2020-07-2455 citations

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.

2020-06-2438 citations

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.

2020-05-0623 citations

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.

2019-10-2931 citations

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).

2019-10-258 citations

ECTRIMS 2019 - Poster Session 1

Multiple Sclerosis Journal2019-09-0113 citations

ACTRIMS 2019 – Posters

Multiple Sclerosis Journal2019-04-0111 citations

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

2019-03-2214 citations

PACTRIMS 2018

Multiple Sclerosis Journal2019-02-019 citations

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

2019-01-069 citations

LACTRIMS 2018

Multiple Sclerosis Journal2018-11-211 citations

THUR 196 Pregnancy outcomes in alemtuzumab-treated rrms patients

Journal of Neurology Neurosurgery & Psychiatry2018-09-13

044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)

Journal of Neurology Neurosurgery & Psychiatry2018-05-24

2 more papers not shown

alemtuzumab GZ402673

Sponsors

Conditions

Phase 1

Phase 3

Phase 4

Related Papers